Literature DB >> 8511589

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.

M Murakami1, M Hibi, N Nakagawa, T Nakagawa, K Yasukawa, K Yamanishi, T Taga, T Kishimoto.   

Abstract

The biological functions of interleukin-6 (IL-6) are mediated through a signal-transducing component of the IL-6 receptor, gp130, which is associated with the ligand-occupied IL-6 receptor (IL-6R) protein. Binding of IL-6 to IL-6R induced disulfide-linked homodimerization of gp130. Tyrosine kinase activity was associated with dimerized but not monomeric gp130 protein. Substitution of serine for proline residues 656 and 658 in the cytoplasmic motif abolished tyrosine kinase activation and cellular responses but not homodimerization of gp130. The IL-6-induced gp130 homodimer appears to be similar in function to the heterodimer formed between the leukemia inhibitory factor (LIF) receptor (LIFR) and gp130 in response to the LIF or ciliary neurotrophic factor (CNTF). Thus, a general first step in IL-6-related cytokine signaling may be the dimerization of signal-transducing molecules and activation of associated tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8511589     DOI: 10.1126/science.8511589

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  148 in total

Review 1.  Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance.

Authors:  K Yamauchi-Takihara; T Kishimoto
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

Review 2.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

3.  Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes.

Authors:  Yibin Xu; Nadia J Kershaw; Cindy S Luo; Priscilla Soo; Michael J Pocock; Peter E Czabotar; Douglas J Hilton; Nicos A Nicola; Thomas P J Garrett; Jian-Guo Zhang
Journal:  J Biol Chem       Date:  2010-05-20       Impact factor: 5.157

4.  IL6 protects MN9D cells and midbrain dopaminergic neurons from MPP+-induced neurodegeneration.

Authors:  Björn Spittau; Xiaolai Zhou; Ming Ming; Kerstin Krieglstein
Journal:  Neuromolecular Med       Date:  2012-07-08       Impact factor: 3.843

5.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells.

Authors:  I Tamm; I Cardinale; T Kikuchi; J G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization.

Authors:  G Courtois; L Bénit; Y Mikaeloff; M Pauchard; M Charon; P Varlet; S Gisselbrecht
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

Review 10.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.